With the landmark identification of a recurrent gene fusion event on chromosome 21 between the TMPRSS2 and ERG genes, prostate cancers are now categorized as "fusion-positive" and "fusion-negative"[12]. The gene discussed is TMPRSS2; the disease is prostate cancer.